Plasminogen activator inhibitor-1 in patients with Kawasaki disease: Diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy

Pediatric Research

Volumn 53, Issue 6, 2003, Pages 983-988

  Senzaki, Hideaki ^a   Kobayashi, Toshiki ^a   Nagasaka, Hironori ^a   Nakano, Hirofumi ^a   Kyo, Shunei ^a   Yokote, Yuji ^a   Sasakid, Nozomu ^a  

^a SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOGLOBULIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANEURYSM; ARTERY WALL; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; SYSTEMIC VASCULITIS;

CORONARY VESSELS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0038617420     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000061566.63383.F4     Document Type: Article

References (45)

1. MacSweeney ST, Powell JM, Greenhalgh RM 1994 Pathogenesis of abdominal aortic aneurysm. Br J Surg 81:935-941
2. Anidjar S, Kieffer E 1992 Pathogenesis of acquired aneurysms of the abdominal aorta. Ann Vasc Surg 6:298-305
3. Parks WC, Mecham RP 1998 Matrix Metalloproteinases. Academic Press, San Diego, pp 1-21
4. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, Welgus HG, Parks WC 1995 Production and localization of 92-KD gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 96:318-326
5. Davies MJ 1998 Aortic aneurysm formation. Lessons from human studies and experimental models. Circulation 98:193-956
6. Tamarina NA, McMillan WD, Shively VP 1997 Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1222:264-271
7. Baramova EN, Bajou K, Remacle JM, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM 1997 Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405:157-162
8. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P 1997 Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332
9. Allaire E, Hasenstab D, Kenagy RD 1998 Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 98:249-255
10. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed MD 1993 Diagnosis and therapy of Kawasaki disease. Circulation 87:1776-1780
11. Senzaki H, Suda M, Noma S, Kawaguchi H, Sakakihara Y, Hishi T 1994 Acute heart failure and acute renal failure in Kawasaki disease. Acta Paediatr Jpn 36:443-447
12. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y 2001 Circulating Matrix Metalloproteinases and Their Inhibitors in Patients with Kawasaki Disease Circulation 104:860-863
13. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M 1991 The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 77:1949-1957
14. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Vague IJ 1997 Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96:761-768
15. Japan Kawasaki disease research committee 1984 Diagnostic guidelines of Kawasaki disease, 4th Rev Ed. Japan Kawasaki disease research committee, Tokyo
16. Brown NJ, Agirbasli MA, Williams GH, Litchfield R, Vaughan DE 1998 Effect of activation and inhibition of the rennin-angiotensin system on plasma PAI-1. Hypertension 32:965-971
17. Woessner JF 1991 Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154
18. Strtler-Stevenson WG 1996 Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148:1345-1350
19. Senzaki H, Gluzband YA, Pak PH, Crow MT, Janicki JS, Kass DA 1998 Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. Circ Res 82:503-512
20. Senzaki H, Gluzband A, Crow MT, Kass DA 2000 β-adrenergic blockade prevents MMP activation and diastolic dysfunction in short-term tachycardia-induced cardiodepression with angiotensin II. Circ Res 86:807-815
21. Vine N, Powell JT 1991 Metalloproteinases in degenerative aortic disease. Clin Sci 816:233-239
22. Carrell TWG, Burnand KG, Wells GMA, Clements JM. Smith A 2002 Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of matrix mettaloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms Circulation 105:477-482
23. Loskutoff DJ, Sawdey M, Mimuro J 1989 Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 9:87-115
24. Nagase H, Enghild JI, Suzuki K, Salvesen G 1990 Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteases and (4-aminophenyl)mercuric acetate. Biochemistry 29:2783-5789
25. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI 1989 Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86:2632-2636
26. Shapiro SD, Fliazar CJ, Broekelmann TJ, Mecham RP, Senior RM, Welgus HG 1995 Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmereric acetate: differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem 270: 6351-6356
27. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D 1997 Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17:439-444
28. Heymans S, Luttun A, Nuyens D, Theilmeier G, Greenmers E, Moons C. Dyspersin GD, Cleutjens JPM, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JFM, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJAP, Carmeliet P 1999 Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5:1135-1142
29. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A. McClure KF, Mitchell PG, Libby P, Lee RT 1999 Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99:3063-3070
30. Praus M, Wauterickx K, Collen D, Gerard RD 1999 Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther 6:227-236
31. Simpson AJ, Booth NA, Moore NR, Bennett B 1991 Distribution of plasminogen activator (PAI-1) in tissues. J Clin Pathol 44:139-143
32. Kikuchi H, Shimada W, Nonaka T, Ueshima S, Tanaka S 1996 Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage. Clin Exp Pharmacol Physiol 23:885-889
33. Mcmurray J, Pfeffer MA 2002 New therapeutic options in congestive heart failure: part I. Circulation 105:2099-2106
34. Deyoung MB, Tom C, Dichek DA 2001 Plasminogen activator inhibitor type 1 increases neointimal formation in balloon-injured rat carotid arteries. Circulation 104:1972-1977
35. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD 1997 Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointimal formation: a gene targeting and gene transfer study in mice. Circulation 96:3180-3191
36. Hasenstab D, Lea H, Clowes AW 2000 Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler Thromb Vasc Biol 20:853-859
37. Gersony WM 1998 Predicting coronary artery aneurysms in Kawasaki disease. Am J Cardiol 81:1162-1164
38. Harada K 1991 Intravenous - globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33:805-810
39. Shinohara M, Sone K, Tomomasa T, Morikawa A 1999 Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 135:465-469
40. Wallace CA, French JW, Kahn SJ, Sherry DD 2000 Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105:E78
41. Lang BA, Silverman ED, Laxer RM 1989 Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr 115:939-943
42. Barron K 1991 Immune abnormalities in Kawasaki disease: prognostic implications and insight into pathogenesis. Cardiol Young 1:206-211
43. Seki T, Healy AM, Fletcher DS, Noguchi T, Gelehrter TD 1999 IL-1β mediates induction of hepatic type 1 plasminogen activator in response to local tissue injury. Am J Physiol 277(Gastrointest Liver Physiol 40):G801-G809
44. Seki T, Gelehrter TD 1996 Interleukin-1 induction of type-1 plasminogen activator inhibitor (PAI-1) gene expression in the mouse hepatocyte line, AML 12. J Cell Physiol 168:648-656
45. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS 1989 Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2(8675):1298-1302